The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 287-300

  Rankin, Naomi J ^a,b   Preiss, David ^a   Welsh, Paul ^a   Burgess, Karl E V ^b   Nelson, Scott M ^b   Lawlor, Debbie A ^c,d   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Advanced lipoprotein testing (ALP); Biomarkers; Cardiovascular disease (CVD); Lipoprotein; Mass spectrometry (MS); Metabolomics; Nuclear magnetic resonance (1H NMR)

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; FATTY ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE; ROSUVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADVANCED LIPOPROTEIN TESTING; ANALYTIC METHOD; ANALYZER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL LABORATORY; CLINICAL PRACTICE; CORONARY ARTERY OBSTRUCTION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DYSLIPIDEMIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MASS SPECTROMETRY; METABOLIC SYNDROME X; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DEVICES; EXERCISE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY;

BIOMARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; EXERCISE; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; METFORMIN; REPRODUCIBILITY OF RESULTS;

EID: 84907728104     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.024     Document Type: Review

References (100)

1. Wishart D.S., Tzur D., Knox C., Eisner R., Guo A.C., Young N., Cheng D., Jewell K., Arndt D., Sawhney S., Fung C., Nikolai L., Lewis M., Coutouly M.A., Forsythe I., Tang P., Shrivastava S., Jeroncic K., Stothard P., Amegbey G., Block D., Hau D.D., Wagner J., Miniaci J., Clements M., Gebremedhin M., Guo N., Zhang Y., Duggan G.E., MacInnis G.D., Weljie A.M., Dowlatabadi R., Bamforth F., Clive D., Greiner R., Li L., Marrie T., Sykes B.D., Vogel H.J., Querengesser L. HMDB: the human metabolome database. Nucleic Acids Res. 2007, 35:D521-D526. (published online Epub Jan). 10.1093/Nar/Gkl923.
2. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., Sinelnikov I., Krishnamurthy R., Eisner R., Gautam B., Young N., Xia J.G., Knox C., Dong E., Huang P., Hollander Z., Pedersen T.L., Smith S.R., Bamforth F., Greiner R., McManus B., Newman J.W., Goodfriend T., Wishart D.S. The human serum metabolome. Plos One 2011, 6. (published online Epub Feb 16 (ARTN e16957 DOI 10.1371/journal.pone.0016957)).
3. Herder C., Karakas M., Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin. Pharmacol. Ther. 2011, 90:52-66. (published online Epub Jul). 10.1038/clpt.2011.93.
4. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin. Chem. 2012, 58:139-147. (published online Epub Jan). 10.1373/clinchem.2011.169573.
5. Sumner L.W., Amberg A., Barrett D., Beale M.H., Beger R., Daykin C.A., Fan T.W.-M., Fiehn O., Goodacre R., Griffin J.L. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007, 3:211-221.
6. Lei Z., Huhman D.V., Sumner L.W. Mass spectrometry strategies in metabolomics. J.Biol. Chem. 2011, 286:25435-25442. (published online Epub Jul 22). 10.1074/jbc.R111.238691.
7. Patti G.J., Yanes O., Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell. Biol. 2012, 13:263-269. (published online Epub Apr). 10.1038/nrm3314.
8. Heather L.C., Wang X., West J.A., Griffin J.L. Apractical guide to metabolomic profiling as a discovery tool for human heart disease. J.Mol. Cell. Cardiol. 2013, 55:2-11. (published online Epub Feb). 10.1016/j.yjmcc.2012.12.001.
9. Nicholson J.K., Holmes E., Kinross J.M., Darzi A.W., Takats Z., Lindon J.C. Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491:384-392. (published online Epub Nov 15). 10.1038/nature11708.
10. World Health Organization Media Centre The Top 10 Causes of Death 2013.
11. Goonewardena S.N., Prevette L.E., Desai A.A. Metabolomics and atherosclerosis. Curr. Atheroscler. Rep. 2010, 12:267-272. (published online Epub Jul). 10.1007/s11883-010-0112-9.
12. Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D'Agostino R.B., Gibbons R., Greenland P., Lackland D.T., Levy D., O'Donnell C.J., Robinson J.G., Schwartz J.S., Shero S.T., Smith S.C., Sorlie P., Stone N.J., Wilson P.W. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J.Am. Coll. Cardiol. 2013, 63:2935-2959. G. American College of Cardiology/American Heart Association Task Force on Practice, 2014 (published online Epub Jul 1). 10.1016/j.jacc.2013.11.005.
13. Martinez-Pinna R., Barbas C., Blanco-Colio L.M., Tunon J., Ramos-Mozo P., Lopez J.A., Meilhac O., Michel J.B., Egido J., Martin-Ventura J.L. Proteomic and metabolomic profiles in atherothrombotic vascular disease. Curr. Atheroscler. Rep. 2010, 12:202-208. (published online Epub May). 10.1007/s11883-010-0102-y.
14. Waterman C.L., Kian-Kai C., Griffin J.L. Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim. Biophys. Acta 2010, 1801:230-234. (published online Epub Mar). 10.1016/j.bbalip.2009.11.004.
15. Folse H.J., Goswami D., Rengarajan B., Budoff M., Kahn R. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study. Atherosclerosis 2014, 236:154-161. (published online Epub 9). http://dx.doi.org/10.1016/j.atherosclerosis.2014.06.027.
16. Ala-Korpela M., Kangas A.J., Soininen P. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics. Genome Med. 2012, 4:36. 10.1186/gm335.
17. Bothwell J.H., Griffin J.L. An introduction to biological nuclear magnetic resonance spectroscopy. Biol. Rev. Camb. Philos. Soc. 2011, 86:493-510. (published online Epub May). 10.1111/j.1469-185X.2010.00157.x.
18. Ernst R.R., Anderson W.A. Application of Fourier transform spectroscopy to magnetic resonance. Rev. Sci. Instrum. 1966, 37:93-102. http://dx.doi.org/10.1063/1.1719961.
19. Meiboom S., Gill D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 1958, 29:688-691. http://dx.doi.org/10.1063/1.1716296.
20. Bictash M., Ebbels T.M., Chan Q., Loo R.L., Yap I.K., Brown I.J., de Iorio M., Daviglus M.L., Holmes E., Stamler J., Nicholson J.K., Elliott P. Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J.Clin. Epidemiol. 2010, 63:970-979. (published online Epub Sep). 10.1016/j.jclinepi.2009.10.001.
21. Teahan O., Gamble S., Holmes E., Waxman J., Nicholson J.K., Bevan C., Keun H.C. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal. Chem. 2006, 78:4307-4318. (published online Epub Jul 1). 10.1021/ac051972y.
22. Bernini P., Bertini I., Luchinat C., Nincheri P., Staderini S., Turano P. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J.Biomol. Nmr 2011, 49:231-243. (published online Epub Apr). 10.1007/s10858-011-9489-1.
23. Pinto J., Domingues M.R., Galhano E., Pita C., Almeida Mdo C., Carreira I.M., Gil A.M. Human plasma stability during handling and storage: impact on NMR metabolomics. Analyst 2014, 139:1168-1177. (published online Epub Mar 7). 10.1039/c3an02188b.
24. Barton R.H., Waterman D., Bonner F.W., Holmes E., Clarke R., Procardis C., Nicholson J.K., Lindon J.C. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol. Biosyst. 2010, 6:215-224. (published online Epub Jan). 10.1039/b907021d.
25. Lutz N.W., Sweedler J.V., Wevers R.A. Methodologies for Metabolomics: Experimental Strategies and Techniques 2013, Cambridge University Press.
26. Dumas M.E., Kinross J., Nicholson J.K. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014, 146:46-62. (published online Epub Jan). 10.1053/j.gastro.2013.11.001.
27. Bodi V., Sanchis J., Morales J.M., Marrachelli V.G., Nunez J., Forteza M.J., Chaustre F., Gomez C., Mainar L., Minana G., Rumiz E., Husser O., Noguera I., Diaz A., Moratal D., Carratala A., Bosch X., Llacer A., Chorro F.J., Vina J.R., Monleon D. Metabolomic profile of human myocardial ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. J.Am. Coll. Cardiol. 2012, 59:1629-1641. (published online Epub May 1). 10.1016/j.jacc.2011.09.083.
28. 1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients. Plos One 2014, 9:e88102. 10.1371/journal.pone.0088102.
29. Madsen R., Lundstedt T., Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal. Chim. Acta 2010, 659:23-33. (published online Epub Feb 5). 10.1016/j.aca.2009.11.042.
30. Wishart D.S. Quantitative metabolomics using NMR. Trac-Trend Anal. Chem. 2008, 27:228-237. (published online Epub Mar). 10.1016/J.Trac.2007.12.001.
31. Gerszten R.E., Wang T.J. The search for new cardiovascular biomarkers. Nature 2008, 451:949-952. (published online Epub Feb 21). 10.1038/nature06802.
32. Kirschenlohr H.L., Griffin J.L., Clarke S.C., Rhydwen R., Grace A.A., Schofield P.M., Brindle K.M., Metcalfe J.C. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med. 2006, 12:705-710. (published online Epub Jun). 10.1038/nm1432.
33. Mallol R., Rodriguez M.A., Brezmes J., Masana L., Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog. Nucl. Magn. Reson. Spectrosc. 2013, 70:1-24. (published online Epub Apr). 10.1016/j.pnmrs.2012.09.001.
34. Kettunen J., Tukiainen T., Sarin A.P., Ortega-Alonso A., Tikkanen E., Lyytikainen L.P., Kangas A.J., Soininen P., Wurtz P., Silander K., Dick D.M., Rose R.J., Savolainen M.J., Viikari J., Kahonen M., Lehtimaki T., Pietilainen K.H., Inouye M., McCarthy M.I., Jula A., Eriksson J., Raitakari O.T., Salomaa V., Kaprio J., Jarvelin M.R., Peltonen L., Perola M., Freimer N.B., Ala-Korpela M., Palotie A., Ripatti S. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 2012, 44:269-276. (published online Epub Mar). 10.1038/ng.1073.
35. Soininen P., Kangas A.J., Wurtz P., Tukiainen T., Tynkkynen T., Laatikainen R., Jarvelin M.R., Kahonen M., Lehtimaki T., Viikari J., Raitakari O.T., Savolainen M.J., Ala-Korpela M. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009, 134:1781-1785. (published online Epub Sep). 10.1039/b910205a.
36. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., Packard C.J., Collins R., Thompson S.G., Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. J.Am. Med. Assoc. 2009, 302:1993-2000. Emerging Risk Factors Collaboration, (published online Epub Nov 11). 10.1001/jama.2009.1619.
37. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J.Clin. Lipidol. 2011, 5:105-113. (published online Epub Mar-Apr). 10.1016/j.jacl.2011.02.001.
38. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation 2009, 119:2396-2404. (published online Epub May 5). 10.1161/CIRCULATIONAHA.108.819359.
39. Superko H.R., Pendyala L., Williams P.T., Momary K.M., King S.B., Garrett B.C. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J.Clin. Lipidol. 2012, 6:496-523. (published online Epub Nov-Dec). 10.1016/j.jacl.2012.03.001.
40. Hiltunen Y., Ala-Korpela M., Jokisaari J., Eskelinen S., Kiviniitty K., Savolainen M., Kesaniemi Y.A. Alineshape fitting model for 1H NMR spectra of human blood plasma. Magn. Reson. Med. 1991, 21:222-232. (published online Epub Oct).
41. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin. Chem. 1991, 37:377-386. (published online Epub Mar).
42. Inouye M., Kettunen J., Soininen P., Silander K., Ripatti S., Kumpula L.S., Hamalainen E., Jousilahti P., Kangas A.J., Mannisto S., Savolainen M.J., Jula A., Leiviska J., Palotie A., Salomaa V., Perola M., Ala-Korpela M., Peltonen L. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 2010, 6:441. (published online Epub Dec 21). 10.1038/msb.2010.93.
43. Goldberg R., Temprosa M., Otvos J., Brunzell J., Marcovina S., Mather K., Arakaki R., Watson K., Horton E., Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J.Clin. Endocrinol. Metab. 2013, 98:3989-3998. (published online Epub Oct). 10.1210/jc.2013-1452.
44. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870. (published online Epub Dec). 10.1016/j.cll.2006.07.006.
45. US Food and Drug Administration Office of InVitro Diagnostic Device Evaluation and Safety K063841 NMR Profiler and NMR Lipo Profile Test 2008, http://www.accessdata.fda.gov/cdrh_docs/pdf6/K063841.pdf.
46. Caulfield M.P., Li S., Lee G., Blanche P.J., Salameh W.A., Benner W.H., Reitz R.E., Krauss R.M. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin. Chem. 2008, 54:1307-1316. (published online Epub Aug). 10.1373/clinchem.2007.100586.
47. Musunuru K., Orho-Melander M., Caulfield M.P., Li S., Salameh W.A., Reitz R.E., Berglund G., Hedblad B., Engstrom G., Williams P.T., Kathiresan S., Melander O., Krauss R.M. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1975-1980. (published online Epub Nov). 10.1161/ATVBAHA.109.190405.
48. Otvos J.D., Rudel L.L., McConnell J.P. Concerns regarding lipoprotein particle measurement by ion mobility analysis. Clin. Chem. 2008, 54:2086-2087. author reply 2088-2089, (published online Epub Dec). 10.1373/clinchem.2008.113795.
49. Cole T.G., Contois J.H., Csako G., McConnell J.P., Remaley A.T., Devaraj S., Hoefner D.M., Mallory T., Sethi A.A., Warnick G.R. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 2013, 59:752-770. Aacc Lipoproteins, Vascular Diseases Division Working Group on Best Practices, (published online Epub May). 10.1373/clinchem.2012.196733.
50. Williams P.T., Zhao X.Q., Marcovina S.M., Otvos J.D., Brown B.G., Krauss R.M. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis 2014, 233:713-720. (published online Epub Apr). 10.1016/j.atherosclerosis.2014.01.034.
51. Lankinen M., Kolehmainen M., Jaaskelainen T., Paananen J., Joukamo L., Kangas A.J., Soininen P., Poutanen K., Mykkanen H., Gylling H., Oresic M., Jauhiainen M., Ala-Korpela M., Uusitupa M., Schwab U. Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activities: a randomized trial (Sysdimet). Plos One 2014, 9:e90352. 10.1371/journal.pone.0090352.
52. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart 2011, 97:442-444. (published online Epub Mar). 10.1136/hrt.2010.214858.
53. Welsh P., Packard C.J., Sattar N. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Curr. Opin. Lipidol. 2008, 19:563-571. (published online Epub Dec). 10.1097/MOL.0b013e32831551e0.
54. Wurtz P., Raiko J.R., Magnussen C.G., Soininen P., Kangas A.J., Tynkkynen T., Thomson R., Laatikainen R., Savolainen M.J., Laurikka J., Kuukasjarvi P., Tarkka M., Karhunen P.J., Jula A., Viikari J.S., Kahonen M., Lehtimaki T., Juonala M., Ala-Korpela M., Raitakari O.T. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 2012, 33:2307-2316. (published online Epub Sep). 10.1093/eurheartj/ehs020.
55. El Harchaoui K., Arsenault B.J., Franssen R., Despres J.P., Hovingh G.K., Stroes E.S., Otvos J.D., Wareham N.J., Kastelein J.J., Khaw K.T., Boekholdt S.M. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 2009, 150:84-93. (published online Epub Jan 20).
56. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128:1189-1197. (published online Epub Sep 10). 10.1161/CIRCULATIONAHA.113.002671.
57. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939. (published online Epub Feb 24). 10.1161/CIRCULATIONAHA.108.816181.
58. Rosenson R.S., Brewer H.B., Chapman M.J., Fazio S., Hussain M.M., Kontush A., Krauss R.M., Otvos J.D., Remaley A.T., Schaefer E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57:392-410. (published online Epub Mar). 10.1373/clinchem.2010.155333.
59. US Food and Drug Administration Office of InVitro Diagnostic Device Evaluation and Safety K113830 Vantera Clinical Analyser 2012, http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113830.pdf.
60. Sawada Y., Akiyama K., Sakata A., Kuwahara A., Otsuki H., Sakurai T., Saito K., Hirai M.Y. Widely targeted metabolomics based on large-scale MS/MS data for elucidating metabolite accumulation patterns in plants. Plant Cell Physiol. 2009, 50:37-47.
61. Fiehn O., Kopka J., Dörmann P., Altmann T., Trethewey R.N., Willmitzer L. Metabolite profiling for plant functional genomics. Nat. Biotechnol. 2000, 18:1157-1161.
62. Zelena E., Dunn W.B., Broadhurst D., Francis-McIntyre S., Carroll K.M., Begley P., O'Hagan S., Knowles J.D., Halsall A., Wilson I.D. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 2009, 81:1357-1364.
63. Teul J., Ruperez F.J., Garcia A., Vaysse J., Balayssac S., Gilard V., Malet-Martino M., Martin-Ventura J.L., Blanco-Colio L.M., Tunon J., Egido J., Barbas C. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J.Proteome Res. 2009, 8:5580-5589. (published online Epub Dec). 10.1021/pr900668v.
64. Barding G.A., Salditos R., Larive C.K. Quantitative NMR for bioanalysis and metabolomics. Anal. Bioanal. Chem. 2012, 404:1165-1179. (published online Epub Sep). 10.1007/S00216-012-6188-Z.
65. Fonville J.M., Maher A.D., Coen M., Holmes E., Lindon J.C., Nicholson J.K. Evaluation of full-resolution J-resolved H-1 NMR projections of biofluids for metabonomics information retrieval and biomarker identification. Anal. Chem. 2010, 82:1811-1821. (published online Epub Mar 1). 10.1021/Ac902443k.
66. Breier M., Wahl S., Prehn C., Fugmann M., Ferrari U., Weise M., Banning F., Seissler J., Grallert H., Adamski J., Lechner A. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. Plos One 2014, 9:e89728. 10.1371/journal.pone.0089728.
67. Tiainen M., Soininen P., Laatikainen R. Quantitative Quantum Mechanical Spectral Analysis (qQMSA) of H NMR spectra of complex mixtures and biofluids. J.Magn. Reson. 2014, 242C:67-78. (published online Epub Feb 18). 10.1016/j.jmr.2014.02.008.
68. Robinette S.L., Bruschweiler R., Schroeder F.C., Edison A.S. NMR in metabolomics and natural products research: two sides of the same coin. Accounts Chem. Res. 2012, 45:288-297. (published online Epub Feb). 10.1021/Ar2001606.
69. Dunn W.B., Broadhurst D., Begley P., Zelena E., Francis-McIntyre S., Anderson N., Brown M., Knowles J.D., Halsall A., Haselden J.N. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 2011, 6:1060-1083.
70. Dumas M.E., Maibaum E.C., Teague C., Ueshima H., Zhou B., Lindon J.C., Nicholson J.K., Stamler J., Elliott P., Chan Q., Holmes E. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal. Chem. 2006, 78:2199-2208. (published online Epub Apr 1). 10.1021/ac0517085.
71. Floegel A., Drogan D., Wang-Sattler R., Prehn C., Illig T., Adamski J., Joost H.G., Boeing H., Pischon T. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. Plos One 2011, 6:e21103. 10.1371/journal.pone.0021103.
72. Beckonert O., Keun H.C., Ebbels T.M., Bundy J., Holmes E., Lindon J.C., Nicholson J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2:2692-2703. 10.1038/nprot.2007.376.
73. Becker E.D., Ferretti J.A., Gupta R.K., Weiss G.H. Choice of optimal parameters for measurement of spin-lattice relaxation-times. 2. Comparison of saturation recovery, inversion recovery, and fast inversion recovery experiments. J.Magn. Reson. 1980, 37:381-394. 10.1016/0022-2364(80)90045-1.
74. Griffin J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 2003, 7:648-654. (published online Epub Oct). 10.1016/J.Cbpa.2003.08.008.
75. Grimes J.H., O'Connell T.M. The application of micro-coil NMR probe technology to metabolomics of urine and serum. J.Biomol. Nmr 2011, 49:297-305. (published online Epub Apr). 10.1007/s10858-011-9488-2.
76. Malet-Martino M., Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J.Pharm. Biomed. Anal. 2011, 55:1-15. (published online Epub Apr 28). 10.1016/j.jpba.2010.12.023.
77. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 2008, 27:1133-1163. (published online Epub Apr 15). 10.1002/sim.3034.
78. Badeau R.M., Honka M.J., Lautamaki R., Stewart M., Kangas A.J., Soininen P., Ala-Korpela M., Nuutila P. Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR gamma agonist. Ann. Med. 2014, 46:18-23. (published online Epub Feb). 10.3109/07853890.2013.853369.
79. Barba I., de Leon G., Martin E., Cuevas A., Aguade S., Candell-Riera J., Barrabes J.A., Garcia-Dorado D. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Reson. Med. 2008, 60:27-32. (published online Epub Jul). 10.1002/mrm.21632.
80. Fischer K., Kettunen J., Würtz P., Haller T., Havulinna A.S., Kangas A.J., Soininen P., Esko T., Tammesoo M.-L., Mägi R. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLOS Med. 2014, 11:e1001606.
81. Kujala U.M., Makinen V.P., Heinonen I., Soininen P., Kangas A.J., Leskinen T.H., Rahkila P., Wurtz P., Kovanen V., Cheng S., Sipila S., Hirvensalo M., Telama R., Tammelin T., Savolainen M.J., Pouta A., O'Reilly P.F., Mantyselka P., Viikari J., Kahonen M., Lehtimaki T., Elliott P., Vanhala M.J., Raitakari O.T., Jarvelin M.R., Kaprio J., Kainulainen H., Ala-Korpela M. Long-term leisure-time physical activity and serum metabolome. Circulation 2013, 127:340-348. (published online Epub Jan 22). 10.1161/CIRCULATIONAHA.112.105551.
82. Skilton M.R., Mikkila V., Wurtz P., Ala-Korpela M., Sim K.A., Soininen P., Kangas A.J., Viikari J.S., Juonala M., Laitinen T., Lehtimaki T., Taittonen L., Kahonen M., Celermajer D.S., Raitakari O.T. Fetal growth, omega-3 (n-3) fatty acids, and progression of subclinical atherosclerosis: preventing fetal origins of disease? The Cardiovascular Risk in Young Finns Study. Am. J. Clin. Nutr. 2013, 97:58-65. (published online Epub Jan). 10.3945/ajcn.112.044198.
83. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011, 42:1282-1288. (published online Epub May). 10.1161/STROKEAHA.110.598789.
84. De Meyer T., Sinnaeve D., Van Gasse B., Tsiporkova E., Rietzschel E.R., De Buyzere M.L., Gillebert T.C., Bekaert S., Martins J.C., Van Criekinge W. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal. Chem. 2008, 80:3783-3790. (published online Epub May 15). 10.1021/ac7025964.
85. Roussel R., Mentre F., Bouchemal N., Hadjadj S., Lievre M., Chatellier G., Menard J., Panhard X., Le Henanff A., Marre M., Le Moyec L., Group D.S. NMR-based prediction of cardiovascular risk in diabetes. Nat. Med. 2007, 13:399-400. (published online Epub Apr). 10.1038/nm0407-399.
86. Erkkila A.T., Schwab U.S., Lehto S., de Mello V.D., Kangas A.J., Soininen P., Ala-Korpela M., Uusitupa M.I. Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: a controlled trial. J.Clin. Lipidol. 2014, 8:126-133. (published online Epub Jan-Feb). 10.1016/j.jacl.2013.09.007.
87. Parish S., Offer A., Clarke R., Hopewell J.C., Hill M.R., Otvos J.D., Armitage J., Collins R. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125:2469-2478. G. Heart Protection Study Collaborative, (published online Epub May 22). 10.1161/CIRCULATIONAHA.111.073684.
88. Hsia J., Otvos J.D., Rossouw J.E., Wu L., Wassertheil-Smoller S., Hendrix S.L., Robinson J.G., Lund B., Kuller L.H. Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1666-1671. G. Women's Health Initiative Research, (published online Epub Sep). 10.1161/ATVBAHA.108.170431.
89. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., Bloomfield H.E., Robins S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563. (published online Epub Mar 28). 10.1161/CIRCULATIONAHA.105.565135.
90. Mora S., Buring J.E., Ridker P.M. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014, 129:553-561. (published online Epub Feb 4). 10.1161/CIRCULATIONAHA.113.005873.
91. van Schalkwijk D.B., de Graaf A.A., Tsivtsivadze E., Parnell L.D., van der Werff-van der Vat B.J., van Ommen B., van der Greef J., Ordovas J.M. Lipoprotein metabolism indicators improve cardiovascular risk prediction. Plos One 2014, 9:e92840. 10.1371/journal.pone.0092840.
92. Mantyselka P., Niskanen L., Kautiainen H., Saltevo J., Wurtz P., Soininen P., Kangas A.J., Ala-Korpela M., Vanhala M. Cross-sectional and longitudinal associations of circulating omega-3 and omega-6 fatty acids with lipoprotein particle concentrations and sizes: population-based cohort study with 6-year follow-up. Lipids Health Dis. 2014, 13:28. 10.1186/1476-511X-13-28.
93. Toth P.P., Grabner M., Punekar R.S., Quimbo R.A., Cziraky M.J., Jacobson T.A. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis 2014, 235:585-591. (published online Epub Aug). 10.1016/j.atherosclerosis.2014.05.914.
94. Makinen V.P., Soininen P., Kangas A.J., Forsblom C., Tolonen N., Thorn L.M., Viikari J., Raitakari O.T., Savolainen M., Groop P.H., Ala-Korpela M. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J.Intern. Med. 2013, 273:383-395. G. Finnish Diabetic Nephropathy Study, (published online Epub Apr). 10.1111/joim.12026.
95. Mantyselka P., Kautiainen H., Saltevo J., Wurtz P., Soininen P., Kangas A.J., Ala-Korpela M., Vanhala M. Weight change and lipoprotein particle concentration and particle size: a cohort study with 6.5-year follow-up. Atherosclerosis 2012, 223:239-243. (published online Epub Jul). 10.1016/j.atherosclerosis.2012.05.005.
96. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J.Am. Coll. Cardiol. 2012, 60:508-516. (published online Epub Aug 7). 10.1016/j.jacc.2012.03.060.
97. Kuller L.H., Grandits G., Cohen J.D., Neaton J.D., Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007, 195:122-128. G. Multiple Risk Factor Intervention Trial Research, (published online Epub Nov). 10.1016/j.atherosclerosis.2006.09.001.
98. Festa A., Williams K., Hanley A.J., Otvos J.D., Goff D.C., Wagenknecht L.E., Haffner S.M. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005, 111:3465-3472. (published online Epub Jun 28). 10.1161/CIRCULATIONAHA.104.512079.
99. Pan Z.Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 2007, 387:525-527. (published online Epub Jan). 10.1007/S00216-006-0687-8.
100. Griffin J.L., Atherton H., Shockcor J., Atzori L. Metabolomics as a tool for cardiac research. Nat. Rev. Cardiol. 2011, 8:630-643. (published online Epub Nov). 10.1038/nrcardio.2011.138.